SARS-COV-2 MRNA vaccine-associated cutaneous vasculitis

During the coronavirus disease 2019 pandemic, global approach was to isolate populations with quarantine procedures to reduce the spread of this deadly virus until effective treatments are found or vaccines are developed. mRNA-based vaccines became available in the United States in March 2020. The F...

Full description

Saved in:
Bibliographic Details
Published inNorthern Clinics of Istanbul Vol. 10; no. 6; pp. 816 - 818
Main Authors Erol, Vedat Bugra, Can, Meryem
Format Journal Article
LanguageEnglish
Published Turkey KARE Publishing 01.01.2023
Kare Publishing
Subjects
Case Report
Coronaviruses
COVID-19 vaccines
Drug dosages
Epidemics
Health aspects
Immunization
Messenger RNA
Pandemics
Quarantine
Severe acute respiratory syndrome coronavirus 2
Vaccination
Vaccines
Vasculitis
United States > US
mRNA vaccines
COVID-19 vaccine
cutaneous vasculitis
leukocytoclasticvasculitis
SARS-CoV-2 virus
Online AccessGet full text

Cover

More Information
Summary:During the coronavirus disease 2019 pandemic, global approach was to isolate populations with quarantine procedures to reduce the spread of this deadly virus until effective treatments are found or vaccines are developed. mRNA-based vaccines became available in the United States in March 2020. The Food and Drug Administration even issued an Emergency Use Authorization for individuals 16 years and older in December 2020. However, these rapid developments have brought along other problems such as possible side effects. As we develop and test a new treatment, it became clear how important side-effect management is. Here, we present a case of cutaneous vasculitis that developed on the fourth day of SARS-CoV-2 mRNA vaccination. The patient was successfully treated with medium-dose methylprednisolone.
ISSN:2148-4902
2536-4553
DOI:10.14744/NCI.2022.22309